Transcriptional plasticity promotes primary and acquired resistance to BET inhibition-Reference-Cited by-同舟云学术

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

Published:2015-09 Issue:7570 Volume:525 Page:543-547
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Rathert Philipp,Roth Mareike,Neumann Tobias,Muerdter Felix,Roe Jae-Seok,Muhar Matthias,Deswal Sumit,Cerny-Reiterer Sabine,Peter Barbara,Jude Julian,Hoffmann Thomas,Boryń Łukasz M.,Axelsson Elin,Schweifer Norbert,Tontsch-Grunt Ulrike,Dow Lukas E.,Gianni Davide,Pearson Mark,Valent Peter,Stark Alexander,Kraut Norbert,Vakoc Christopher R.,Zuber Johannes

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature14898.pdf

Reference55 articles.

1. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528 (2011)

2. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533 (2011)

3. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011)

4. Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278–282 (2014)

5. Puissant, A. et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308–323 (2013)

Cited by 422 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver-targeting chimeras as a potential modality for the treatment of liver diseases;Journal of Controlled Release;2024-10

2. MYC plus class IIa HDAC inhibition potentiates mitochondrial dysfunction in non-small cell lung cancer;2024-09-08

3. Oncogenic Enhancers in Leukemia;Blood Cancer Discovery;2024-08-01

4. Coupling proximity biotinylation with genomic targeting to characterize locus-specific changes in chromatin environments;2024-07-26

5. Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis;Cell Reports;2024-07